No Data
No Data
Axsome Therapeutics' CNS Portfolio Poised for Major Growth - Analyst Predicts Strong Future
Needham Starts Axsome at Buy, Cites Revenue Growth Potential
Axsome Therapeutics Price Target Maintained With a $131.00/Share by RBC Capital
RBC Capital Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Raises Target Price to $131
RBC Capital Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)
Needham Initiates Axsome Therapeutics(AXSM.US) With Buy Rating, Announces Target Price $130
Salmon Klein : are you in $Macrogenics (MGNX.US)$ ? tell me when good to jump in
MangoXXXX Salmon Klein: Now
Meticulous Trader Salmon Klein: Do your own research , I think hovering in bottom and buy signal from pattern about to begin , do not follow me blindly my
Salmon Klein Meticulous Trader: I am waiting to reach 14.8 or so, but I am busy working, if it reached the bottom and you are in...any good feedback is always very welcomed bro...just that so thanks
Meticulous Trader Salmon Klein: Double higher bottom in intra-day might not hit below 14ish or if so still chance for 2 more trading sideways days, I am almost 25% down ( reason holding beyond top) anyway